Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The time-varying association between previous antibiotic use and antibiotic resistance
Avi Baraz, Michal Chowers, Daniel Nevo, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 390.e1-390.e4
Open Access | Times Cited: 14

Showing 14 citing articles:

RETRACTED: Empowering Low- and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward
Mohammed Kanan Alshammari, Maali Ramadan, Hanan Haif, et al.
Antibiotics (2023) Vol. 12, Iss. 10, pp. 1504-1504
Open Access | Times Cited: 30
Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it’s even arrived?
Chiara Russo, Alessio Mesini, Marcello Mariani, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 4, pp. 624-631
Open Access | Times Cited: 5
Prevalence and Antibiotic Resistance Patterns of Methicillin-Resistant Staphylococcus aureus (MRSA) in a Hospital Setting: A Retrospective Study from 2018 to 2022
Tian Lan, Bin Zhang, Jin Lu Liu, et al.
Indian Journal of Microbiology (2024) Vol. 64, Iss. 3, pp. 1035-1043
Closed Access | Times Cited: 4
The Molecular Mechanisms and Therapeutic Potential of Cranberry, D-Mannose, and Flavonoids against Infectious Diseases: The Example of Urinary Tract Infections
Πέτρος Ιωάννου, Stella Baliou
Antibiotics (2024) Vol. 13, Iss. 7, pp. 593-593
Open Access | Times Cited: 4
Impact of meropenem exposure on fluoroquinolone and carbapenem resistance in Pseudomonas aeruginosa infection in inpatients in a Japanese university hospital: Insights into oprD mutations and efflux pump overexpression
Tadanori Yamochi, Kazuhisa Ugajin, Rintaro On, et al.
Journal of Global Antimicrobial Resistance (2025)
Open Access
Penicillin allergy as an instrumental variable for estimating antibiotic effects on resistance
Yaki Saciuk, Daniel Nevo, Michal Chowers, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Bayesian network modeling of patterns of antibiotic cross-resistance by bacterial sample source
Stacey S. Cherny, Michal Chowers, Uri Obolski
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 11
How can we tackle the overuse of antibiotics in low- and middle-income countries?
Giorgia Sulis, Sena Sayood, Sumanth Gandra
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 11, pp. 1189-1201
Closed Access | Times Cited: 8
A predictive score for the result of carbapenem-resistant Enterobacterales and vancomycin-resistant enterococci screening
F. Stordeur, Anis Larbi, Killian Le Neindre, et al.
Journal of Hospital Infection (2024) Vol. 148, pp. 20-29
Closed Access | Times Cited: 2
Advanced antibacterial materials for the prevention of nosocomial infections
Chun Long Tommy Kong, X. Wang, Huipeng Li, et al.
Interdisciplinary Nursing Research (2024) Vol. 3, Iss. 2, pp. 97-108
Open Access | Times Cited: 2
Clinical Characteristics of and Risk Factors for Subsequent Carbapenemase-producing Enterobacterales (CPE) Bacteraemia in Rectal CPE Carriers
Sung‐Woon Kang, Somi Park, Areum Kim, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 5, pp. 106959-106959
Closed Access | Times Cited: 5
Multidrug-Resistant Bacterial Colonization and Infections in Large Retrospective Cohort of Mechanically Ventilated COVID-19 Patients1
Davide Mangioni, Liliane Chatenoud, Jacopo Colombo, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 8
Open Access | Times Cited: 3
ELIMINATE Phase 2 Trial: Outcomes from the Part 1 Open-Label Dose Regimen Selection Portion of a 2-Part Trial Testing LBP-EC01, a CRISPR-Cas3-Enhanced Bacteriophage Cocktail, in Uncomplicated Urinary Tract Infections
Paul Kim, Ana M. Sánchez, J. Kime, et al.
(2024)
Closed Access
The straight and narrow: a game theory model of broad- and narrow-spectrum empiric antibiotic therapy
Maya Diamant, Uri Obolski
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top